Abstract
Precision oncology implies customizing treatment for each individual and cancer based on unique molecular and biologic characteristics. In the pregenomic era cancers are classified based on tumor site and histology.
In the upcoming genomic era malignant diseases are reclassified based on molecular and biologic characteristics which results in increased number of cancer types. In the future, more and more identifiers of tumor diversity will be defined and the end of the pregenomic era of rare tumors can be expected.